Biologics and JAK inhibitors show efficacy in Crohn's-associated orofacial granulomatosis

This retrospective cohort provides the first controlled phenotype comparison and largest treatment-response dataset for orofacial granulomatosis in Crohn's disease, offering guidance on drug selection and anti-TNF dose optimization.

📅 Journal publication: Sep 3, 2026 · Last updated: Oct 7, 2026

orofacial granulomatosisCrohn's diseaseinfliximabadalimumabustekinumabrisankizumabupadacitinibvedolizumabanti-TNFanti-IL23JAK inhibitortherapeutic drug monitoringretrospective cohortupper GI Crohn'sphenotype Gastroenterology / Hepatology

Also in Rheumatology / Immunology

Background Information

Biologics show promise for Crohn's disease with orofacial granulomatosis.

Orofacial granulomatosis (OFG) linked with Crohn's disease (CD) presents distinct clinical challenges and may require specialized treatment strategies. In patients with OFG-associated CD, remission was achieved with infliximab (55%), adalimumab (59%), and other biologics, highlighting the effectiveness of advanced therapies. This study identifies unique CD phenotypes in OFG and supports the use of various biologic and Janus kinase inhibitor therapies, emphasizing the need for dose optimization. Advanced therapies, particularly biologics and JAK inhibitors, show efficacy in treating OFG-associated CD.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Lees RD, Patel P, Young G, Beck L, Marin AM, Parkinson D, Pele L, Parkes M, Sanderson J, Herbert C, Hullah E, Lamb CA, Mawdsley J, Speight RA

Citation: Lees RD, Patel P, Young G, et al. Orofacial granulomatosis associated with Crohn's disease: clinical phenotype and response to biologics and Janus kinase inhibitor therapy in a large multi-center cohort. Journal of Crohn's & colitis. 2026;20(9). doi:10.1093/ecco-jcc/jjag139

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →